Biologics, therapies made inside or of living cells, are a growing share of pharmaceutical sales. But the cost of these miracle treatments makes them unaffordable for many. New FDA guidance may help.
As concern grows for the escalating prices of prescription drugs, a novel approach to lower the price of drugs to treat hepatitis C in Louisiana holds promise, a policy expert says.
The Trump administration's proposal to lower drug prices focuses on discounts. A health policy scholar argues that the US could learn from Europe's system of measuring drug value and effectiveness.
The logic behind U.S. president Donald Trump's proposal that Canada and other countries have been “free-riding” off high prices in the United States is bizarre at best.
The rising costs of generic drugs have led to outcries. In a search for solutions, four hospital systems are proposing to make drugs on their own. Could their idea work?
Rather than being designed by chemists, this class of pharmaceuticals is produced by living cells. Here's where they come from and how they work.
Drug prices in Australia are three times higher than in New Zealand. A key reason is the lack of transparency about taxpayer subsidies for Big Pharma and the companies' own finances.
An independent expert provides his pick of the most notable drugs added to the PBS on May 1, 2017.
The Orphan Drug Act was enacted 34 years ago to encourage the development of drugs for rare diseases. Drug companies were guaranteed seven years of exclusivity. Then the rush was on to run up prices.
Australia is spending more than A$500 million a year too much for pharmaceuticals because of a little known loophole that allows drug companies to overcharge the government.
The rising cost of drugs is more worrisome to most Americans than problems with Obamacare. Could proposals in California and Ohio help?
Pharmaceutical companies aim to make a profit, but it took an industry insider to blow the whistle on some exorbitant drug costs the NHS was paying.
Clinton, who named drug companies among her enemies in this week's debate, is pushing populist-inspired policies that could hamper the flow of new medicines.
Most of us would agree that cancer drugs should be listed on the PBS, no matter how dear. But our health system can't afford all of them. How then are decisions about which drugs to subsidise made?
Over the next few weeks, the trade minister will be under intense pressure to renege on the government’s commitment to reject anything in the Trans Pacific Partnership that could undermine the PBS.
Hope, fear, and desperation, along with the unique characteristics of the cancer drug market, create a “perfect storm” that continues to drive up prices for cancer drugs.